Literature DB >> 10070921

Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine.

C D Flombaum1, J A Mouradian, E S Casper, R A Erlandson, F Benedetti.   

Abstract

Three patients with pancreatic carcinoma treated with gemcitabine for 1 year developed clinical and laboratory findings compatible with an indolent form of the hemolytic-uremic syndrome. Renal biopsy specimens in two of these patients showed the characteristic features of thrombotic microangiopathy, and a skin biopsy specimen from the third patient, who presented with livedo reticularis, showed intravascular fibrin deposition. Thrombotic microangiopathy may represent a toxic effect of long-term gemcitabine therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10070921     DOI: 10.1016/s0272-6386(99)70194-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  13 in total

1.  Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.

Authors:  Adarsh Das; Andrew Dean; Tim Clay
Journal:  BMJ Case Rep       Date:  2019-04-08

2.  Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.

Authors:  Florence Daviet; Franck Rouby; Pascale Poullin; Julie Moussi-Francès; Marion Sallée; Stéphane Burtey; Julien Mancini; Florence Duffaud; Renaud Sabatier; Bertrand Pourroy; Aurélie Grandvuillemin; Steven Grange; Véronique Frémeaux-Bacchi; Paul Coppo; Joëlle Micallef; Noémie Jourde-Chiche
Journal:  Br J Clin Pharmacol       Date:  2018-12-18       Impact factor: 4.335

3.  Livedo reticularis and related disorders.

Authors:  Steven M Dean
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-04

4.  ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy.

Authors:  Peter G Bittar; Myles S Nickolich; Oluwatoyosi A Onwuemene
Journal:  J Clin Apher       Date:  2017-09-23       Impact factor: 2.821

5.  [A 42 year old patient with bilateral loss of sight and hypertension. Gemcitabine-associated thrombotic microangiopathy (TMA)].

Authors:  A Schmidt; N Schwella; U Helmchen; D von Renteln; K Caca
Journal:  Internist (Berl)       Date:  2008-08       Impact factor: 0.743

6.  Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.

Authors:  Maximilien Grall; Florence Daviet; Noémie Jourde Chiche; François Provot; Claire Presne; Jean-Philippe Coindre; Claire Pouteil-Noble; Alexandre Karras; Dominique Guerrot; Arnaud François; Ygal Benhamou; Agnès Veyradier; Véronique Frémeaux-Bacchi; Paul Coppo; Steven Grangé
Journal:  BMC Nephrol       Date:  2021-07-21       Impact factor: 2.388

Review 7.  Nephrotoxicity of recent anti-cancer agents.

Authors:  Norbert Lameire
Journal:  Clin Kidney J       Date:  2013-11-26

Review 8.  Cancer-associated thrombotic microangiopathy.

Authors:  K Govind Babu; Gita R Bhat
Journal:  Ecancermedicalscience       Date:  2016-06-28

9.  Gemcitabine induced hemolytic uremic syndrome.

Authors:  Seyed-Ali Sadjadi; Pavan Annamaraju
Journal:  Am J Case Rep       Date:  2012-05-25

Review 10.  Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.

Authors:  Hye Won Lee; Moon Jae Chung; Huapyong Kang; Heun Choi; Youn Jeong Choi; Kyung Joo Lee; Seung Woo Lee; Seung Hyuk Han; Jin Seok Kim; Si Young Song
Journal:  Gut Liver       Date:  2014-01-13       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.